First, in June 2007, GSK launched its fluticasone follow-on product, Veramyst, in the United States. This product has a broader label than other INS products: the package insert indication ...

denying a label extension because there was no evidence to show a reduction of flare-ups. It’s a blow for GSK, which hopes that Trelegy (fluticasone furoate+umeclidinium+vilanterol) will help to ...

Mylan obtained approval to market the generic dubbed Wixela Inhub in three strengths: fluticasone propionate ... which prompted an amendment to the label for certain inhaled corticosteroids ...